Abiopharma

XPEL Reports Revenue Growth of 13.1% to $117.4 million, EBITDA Growth of 17.8% to $17.0 million in First Quarter 2026

Oncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer’s Disease

Rand Capital Reports First Quarter Fiscal Year 2026 Results

Liquidia Corporation to Participate in Upcoming Investor Conferences

Runway Growth Finance Corp. Announces Second Quarter 2026 Dividend of $0.33 per Share

Medalist Diversified, Inc. (NASDAQ: MDRR) Announces DST Sponsor Platform; Inaugural Tesla-Leased Offering Available to Accredited 1031 Investors

The CLAL INSURANCE ENTERPRISES HOLDINGS LTD Periodic Report for 2025- translated version [The Hebrew periodic report was published on March 26, 2026]

Lumen Technologies, Inc. Announces Offering of Senior Notes Due 2037 and Concurrent Tender Offers

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases